Dr. Elyse A. Lambiase, MD

Dr. Lambiase practices at Operating Room / One Day Surgical Patients - HOPD in Chicago, Illinois.

Dr. Lambiase's NPI, 1912992561, was assigned on September 20, 2005. Dr. Lambiase graduated from Harvard Medical School in 1979. Dr. Lambiase holds Illinois license 036064464.

Dr. Lambiase's primary practice is Operating Room / One Day Surgical Patients - HOPD, at 5140 N California Ave, Chicago, IL 60625.

Dr. Lambiase's primary practice is Operating Room / One Day Surgical Patients - HOPD in Chicago, Illinois. Dr. Lambiase is also affiliated with Swedish Hospital. The medical group on file is Endeavor Health Medical Group. Dmand AI also links Dr. Lambiase to 2 more hospitals, 3 group practices and clinics and 2 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Lambiase practices, 7 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Lambiase's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Lambiase is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Lambiase's licenses on file in 3 states: Illinois, Wisconsin and Ohio.

Dmand AI lists breast cancer, chronic anemia, colorectal cancer, lung cancer, multiple myeloma, prostate cancer and purpura and thrombocytopenia among the conditions Dr. Lambiase treats.

CMS data shows 882 Medicare services from Dr. Lambiase across 6 procedure codes in 2024, for 168 Medicare patients. Medicare paid $45,979 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 168 Medicare patients who saw Dr. Lambiase in 2024. The largest group is 65 to 74, with 67 patients. 75% of them have high blood pressure, and 71% have high cholesterol. 45% are also on Medicaid. Their average risk score is 1.67, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Lambiase's median patient age at 57, with 85% women.

In 2024, Dr. Lambiase wrote 708 Medicare Part D claims for 108 patients. 85% of them were for generic drugs. CMS names the drug for 586 of them, across 17 drugs with 11 or more claims each, at $568,982 in total drug cost. In 2023, CMS named 425 claims across 9 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 85 out of 100 for Dr. Lambiase for performance year 2024, reported as part of a group. Dr. Lambiase accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 1 paper to Dr. Lambiase. Dr. Lambiase's most frequent co-author is Kenneth L. Janson, MD.

Dmand AI links Dr. Lambiase to 16 clinical trials, 8 of them phase 3 studies. 9 are still active or recruiting. Conditions studied include Breast Neoplasms, Carcinoma, Non-Small-Cell Lung and Breast Diseases. National Cancer Institute (NCI) sponsors the most, 10. Open Payments lists research payments to Dr. Lambiase that name 1 trial.

CMS Open Payments shows 494 general payments to Dr. Lambiase from 42 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 100% of the total. Novartis Pharmaceuticals Corporation paid the most, $1,808. It also lists 2 research payments totaling $14,088 in 2021, naming 1 clinical trial.

Dr. Lambiase graduated from Harvard Medical School in 1979. Dr. Lambiase is a member of ACP and ASCO.

Dr. Lambiase is in network with 16 carriers, including Aetna, Cigna and Elevance. PPO plans come from the most carriers, 11. Check the plan with the practice before a visit.